The company reports that all 26 cataract procedures were completed robotically without conversion to manual surgery. The latest clinical experience adds 14 procedures to the 12 first-in-human cases announced earlier in 2026. The procedures formed part of ForSight Robotics’ ongoing first-in-human study and were performed by Dr Alexey Rapoport. Dr Robert T. Ang, Senior Consultant and Head of Cornea and Refractive Surgery Services at the Asian Eye Institute in the Philippines, is serving as principal investigator.
One of the most relevant aspects of the update is the reported integration of the JASPER platform into a conventional cataract surgery pathway. According to ForSight Robotics, patients received either topical anaesthesia or mild sedation and were discharged on the same day. These details suggest that the robotic platform was used alongside established outpatient cataract protocols rather than requiring a fundamentally different care model. This distinction may be important for future adoption. New surgical technologies must demonstrate more than technical capability; they must also fit safely and efficiently into existing clinical environments, staffing models and patient pathways. The results announced to date are company-reported and form part of an ongoing early-stage clinical programme. Further clinical evidence and regulatory review will be required before the platform can enter routine commercial use.
JASPER is designed to support the complete cataract procedure through surgeon-controlled telemanipulation. The ophthalmic surgeon remains in control throughout the operation, directing the robotic instruments from an ergonomic console. The platform combines:
Together, these capabilities are intended to enhance precision, stability and control during microsurgery. The system is also designed to reduce some of the physical demands placed on ophthalmic surgeons, who can experience musculoskeletal strain from sustained operating postures. The current programme concerns robotic assistance under direct surgeon control. It should not be interpreted as autonomous cataract surgery.
Cataract surgery is one of the world’s most frequently performed surgical procedures. ForSight Robotics states that more than 30 million procedures are carried out globally each year, while a much larger population still requires treatment. Against this backdrop, ophthalmic robotics could have implications beyond individual procedures. If supported by robust clinical evidence and regulatory approval, the technology may help improve surgical consistency, support surgeon ergonomics and create new opportunities to expand access to cataract care. However, the path from first-in-human feasibility to widespread clinical adoption is substantial. Future assessment will need to consider safety, visual outcomes, workflow efficiency, training requirements, cost-effectiveness, maintenance and the platform’s performance across a broader range of patients and surgical settings.
The expanded first-in-human experience provides ForSight Robotics with further evidence as it progresses towards additional clinical studies and regulatory submissions. For ophthalmology leaders, the milestone offers an early view of how robotics could become integrated into high-volume anterior-segment surgery while preserving surgeon oversight. The more consequential questions will concern reproducibility, measurable clinical benefit and whether the technology can deliver practical value at scale.JASPER remains under development and has not yet been approved for commercial use. Its progression will therefore be closely watched by cataract surgeons, ophthalmology providers and medical-technology leaders assessing the future role of robotics in eye care.